At the JP Morgan Healthcare Conference, while addressing the state of the company in 2025, experts from Gilead Sciences touted the company’s manufacturing infrastructure as one of its key advantages ...
In the mRNA vaccine maker’s 2024 Shareholder Letter, CEO Stéphane Bancel reflected upon the company’s second year manufacturing and distributing vaccines for COVID-19, admitting that sales in the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback